ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT

Oncogene

Volumn 35, Issue 28, 2016, Pages 3681-3691

  Debruyne, D N ^a   Bhatnagar, N ^a   Sharma, B ^a   Luther, W ^a   Moore, N F ^a   Cheung, N K ^b   Gray, N S ^c,d   George, R E ^a,d  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 4 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 2 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO]PYRIMIDINE; ANAPLASTIC LYMPHOMA KINASE; AXL PROTEIN TYROSINE KINASE; CADHERIN; CERITINIB; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VIMENTIN; AXL RECEPTOR TYROSINE KINASE; CRIZOTINIB; NVP-TAE684; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONE;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ECTOPIC EXPRESSION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; IC50; INDUCED RESISTANCE; NEUROBLASTOMA; NEUROBLASTOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NEUROBLASTOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SULFONES;

EID: 84949008402     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.434     Document Type: Article

References (47)

1. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 2013; 31: 3987-3996.
2. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-1079.
3. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
4. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-974.
5. George RE, Sanda T, Hanna M, Frohling S, Luther W 2nd, Zhang J et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008; 455: 975-978.
6. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008; 455: 967-970.
7. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455: 930-935.
8. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM et al. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res 2010; 16: 4353-4362.
9. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T et al. The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell 2012; 22: 117-130.
10. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010; 70: 10038-10043.
11. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011; 19: 679-690.
12. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L et al. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci USA 2007; 104: 270-275.
13. Chen J, Jiang C, Wang S. LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. J Med Chem 2013; 56: 5673-5674.
14. Heuckmann JM, Holzel M, Sos ML, Heynck S, Balke-Want H, Koker M et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011; 17: 7394-7401.
15. Lemke G. Biology of the TAM receptors. Cold Spring Harb Perspect Biol 2013; 5: a009076.
16. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M et al. An epithelialmesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013; 19: 279-290.
17. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012; 44: 852-860.
18. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res 2010; 70: 1544-1554.
19. Anastassiou D, Rumjantseva V, Cheng W, Huang J, Canoll PD, Yamashiro DJ et al. Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer 2011; 11: 529.
20. Blick T, Hugo H, Widodo E, Waltham M, Pinto C, Mani SA et al. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44 (hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J Mammary Gland Biol Neoplasia 2010; 15: 235-252.
21. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010; 107: 15449-15454.
22. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
23. Mudduluru G, Allgayer H. The human receptor tyrosine kinase Axl gene - promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation. Biosci Rep 2008; 28: 161-176.
24. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 2011; 30: 2888-2899.
25. Mark MR, Chen J, Hammonds RG, Sadick M, Godowsk PJ. Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl. J Biol Chem 1996; 271: 9785-9789.
26. Goruppi S, Yamane H, Marcandalli P, Garcia A, Clogston C, Gostissa M et al. The product of a gas6 splice variant allows the release of the domain responsible for Axl tyrosine kinase receptor activation. FEBS Lett 1997; 415: 59-63.
27. Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011; 30: 2581-2586.
28. Wu Z, Moghaddas Gholami A, Kuster B. Systematic identification of the HSP90 candidate regulated proteome. Mol Cell Proteomics 2012; 11: M111 016675.
29. Korshunov VA. Axl-dependent signalling: a clinical update. Clin Sci (Lond) 2012; 122: 361-368.
30. Stenhoff J, Dahlback B, Hafizi S. Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts. Biochem Biophys Res Commun 2004; 319: 871-878.
31. Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, Spizz G et al. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol 1996; 16: 135-145.
32. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 2006; 103: 5799-5804.
33. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 2010; 107: 1124-1129.
34. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene 2011; 30: 1436-1448.
35. Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD et al. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther 2013; 12: 2541-2558.
36. Hong J, Peng D, Chen Z, Sehdev V, Belkhiri A. ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res 2013; 73: 331-340.
37. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res 2009; 69: 6871-6878.
38. Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014; 26: 682-694.
39. Duijkers FA, Meijerink JP, Pieters R, van Noesel MM. Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration. Gene 2013; 521: 62-68.
40. Kim HR, Kim WS, Choi YJ, Choi CM, Rho JK, Lee JC. Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation. Mol Oncol 2013; 7: 1093-1102.
41. Wilson C, Ye X, Pham T, Lin E, Chan S, McNamara E et al. AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs. Cancer Res 2014; 74: 5878-5890.
42. Krishnamoorthy GP, Guida T, Alfano L, Avilla E, Santoro M, Carlomagno F et al. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation. J Biol Chem 2013; 288: 17481-17494.
43. Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet 2015; 47: 864-871.
44. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-509.
45. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet 2006; 38: 500-501.
46. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550.
47. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47: 331-385.